Pharma giant Merck filed a suit in federal court in Washington over a federal law that empowers Medicare for the first time to negotiate prices directly with drugmakers. This is "the drug
industry’s most significant move so far to fight back against a substantial change to health policy, which will go into effect in 2026," per
The New York Times. "Democrats pushed
through the Medicare-negotiation program last summer as a provision of the Inflation Reduction Act, framing it as a way of lowering drug prices."
Read the whole story at The New York Times »
